Table 1 Number of dogs per response classification receiving concomitant anti-pruritic medications with RESPIT at D270+
From: Effectiveness of regionally-specific immunotherapy for the management of canine atopic dermatitis
Concomitant anti-pruritic medication | Poor n = 18 | Fair n = 26 | Good n = 39 | Excellent n = 20 |
|---|---|---|---|---|
None | 4 (22%) | 6 (23%) | 13 (33%) | 18 (90%) |
Oral glucocorticoid | 7 (39%) | 10 (38%) | 17 (44%) | 0 (0%) |
Cyclosporine | 4 (22%) | 7 (27%) | 7 (18%) | 0 (0%) |
Oclacitinib | 0 (0%) | 0 (0%) | 2 (5%) | 0 (0%) |
Antihistamine | 3 (17%) | 5 (19%) | 1 (3%) | 1 (5%) |
Topical glucocorticoid, including otic | 1 (6%) | 1 (4%) | 0 (0%) | 1 (5%) |